

# Hypertrophic Obstructive Cardiomyopathy

HOCM (a.k.a. IHSS) is an autosomal dominant genetic disorder of cardiac sarcomeres of which a subset of patients (~25%) have a dynamic obstruction to left ventricular outflow at rest, while other patients have dynamic outflow obstruction only during exertion and some have no appreciable outflow obstruction (despite being genetically susceptible)

## ANESTHETIC CONSIDERATIONS:

- Cardiac dysfunction
  - Dynamic LV outflow obstruction
  - Mitral regurgitation
  - Hypertrophy with diastolic dysfunction and ischemia
  - Arrhythmias / sudden death
  - CPR ineffective??
- Medications
  - Beta-blockers or CCB
  - Anti-arrhythmics
  - Anti-coagulants
  - Diuretics
- Pacemakers or AICD

## ANESTHETIC GOALS:

- Overall, goal is to minimize systolic pressure gradient between LV and aorta
- Avoid hypotension (phenylephrine)
  - Profound hypotension in setting of **hypovolemia**, decreased preload / afterload or increased contractility → always keep full, full, full (first treatment for hypotension!!) and keep afterload up, up, up (second treatment for hypotension is pure vasoconstrictor), finally consider decreasing contractility (volatile good for this)
- Contractility: avoid increasing (beta blockers, CCB, halothane etc.)
- Rate: avoid tachycardia
- Rhythm: strict NSR
- Afterload: Maintain
- Preload: FULL
- MVO<sub>2</sub>: monitor for ischemia

## HISTORY

- Many patients may have minor or no symptoms (many individuals diagnosed during family screening)
- Resting pressure gradient between LV outflow tract and aorta present in only ~25% of patients whereas other patients only have a gradient with exertion
- LVOT Obstruction
  - Dyspnea on exertion (90%)
  - Pre-syncope or syncope
  - Postural light-headedness
- Hypertrophy
  - Chest pain (25-30%)
    - Majority have normal angiogram
    - Commonly precipitated or worsened by heavy meals
  - Diastolic dysfunction
- Arrhythmias
  - Supraventricular Arrhythmias (A-fib, A-flutter)
    - Can proceed to ventricular arrhythmias
  - Ventricular Arrhythmias
    - Ventricular premature beats
    - Non-sustained VT
      - Increased risk for SCD (8.6% per year vs. 1% per year)
- Sudden Cardiac Death
  - Risk factors
    - Syncope and / or family history of SCD
    - LV wall thickness > 30 mm
    - Non-sustained ventricular tachycardia
    - Abnormal blood pressure response with exercise

## PHYSICAL

- **GENERAL**
  - May be normal
- **CVS**
  - LV outflow obstruction
    - Harsh crescendo-decrescendo systolic murmur
    - May also reflect MR
    - Worsened with decreased SVR, pre-load:
      - Squatting to upright posture
      - Valsalva maneuver
    - Improved with increased pre-load, increased SVR
      - Handgrips

- Raising legs
  - May have evidence of diastolic dysfunction
    - S3 or S4
- **RESP**
  - Crackles / wheeze due to pulmonary congestion

## INVESTIGATIONS

- **Labs**
  -
- **Imaging**
  - **EKG**
    - Normal EKG is uncommon (only 7%)
    - LVH with strain
    - Prominent abnormal Q waves in inferior and lateral leads
    - P-wave abnormalities
    - LAD
  - **Echocardiography**
    - Hypertrophy:
      - Variable patterns: septal hypertrophy, apical hypertrophy, LV free wall, RV hypertrophy
      - DDx: HTN, Aortic Stenosis, Athlete's Heart, Fabry's disease
    - Resting LVOT obstruction present in only ~25% of patients
    - Mitral regurgitation
      - Obstructive HOCM
        - Almost all patients
        - Secondary to systolic anterior movement of mitral valve (SAM)
      - Non-obstructive HCM
        - 20-30% of patients and normally mild
    - Diastolic Dysfunction
      - Present in most patients
      - A risk factor for death or sustained VT
  - **MIBI**
    - Often abnormal in patients with HOCM:
      - Asymmetric distribution of hypertrophy
      - Microvascular disease
  - **Cardiac MRI**
    - Useful if suboptimal Echo or hypertrophy localized to apex
  - **Catheterization**
    - Assessment of severity of LV obstruction requires estimation of three hemodynamic factors
      - Cardiac output
      - LV filling pressure or left atrial pressure
      - LV outflow tract pressure gradient
    - Performed if Echo inadequate or obstruction complex

## OPTIMIZATION

- Need to assess degree of medical optimization from:
  - LVOT obstruction (want to reduce LVOT gradient)
    - Preoperative sedation to prevent anxiety induced sympathetic stimulation
    - Replace any preoperatively **fluid** deficit
    - Is the patient adequately **beta-blocked or CCB?**
    - Is there **any surgical procedure** that could be performed?
      - LV myectomy
        - Patients with obstructive HCM who are severely symptomatic NYHA class III or IV or have recurrent syncope despite pharmacologic therapy are candidates for LV myectomy (i.e. > 50 mmHg at rest)
        - Can eliminate or significantly decrease LVOT obstruction
      - MVR, mitral valve plication
    - Non-surgical approach
      - Alcohol ablation of septal perforators
  - Hypertrophy
    - Ischemia
      - Is an adequate etiology of ischemia been sought and can this be further optimized?
    - Diastolic dysfunction
      - Does the patient require diuretics if significant SOB or obvious clinical CHF?
      - Careful with decreased preload causing increased LVOT obstruction
  - Arrhythmias
    - Does this patient require medical management (amiodarone) or pacemaker / AICD prior to procedure?
    - Current 2002 ACC / AHA / NASPE guidelines suggest pacemaker only for HCM patients with sinus node dysfunction or AV block
    - DDD pacing was previously used as alternative to myectomy to improve symptoms – not supported by outcome data (Uptodate)
  - Anticoagulation

- Patients with paroxysmal or chronic atrial fibrillation are at high risk for thromboembolism - long term anticoagulation
- May have to reverse, hold or convert to heparin for surgery

#### ANESTHETIC OPTIONS

- Either general anesthesia or regional anesthesia OK if hemodynamic goals can be met
- Some feel that neuraxial anesthesia relatively contra-indicated due to unfavorable alteration in physiology (i.e. decreased preload, decreased afterload, increased HR)

#### ANESTHETIC SETUP

- **Drugs**
  - Alpha agonists (e.g. phenylephrine) preferred to maintain SVR
  - Beta-blockers or CCB
  - Anti-arrhythmics (e.g. amiodarone, lidocaine) for immediate treatment of arrhythmias
- **Equipment**
  - Patients should have full hemodynamic monitoring to ensure anesthetic goals are met
    - Arterial line
    - CVP
    - 5 lead EKG
  - Have immediate availability for cardioversion or pacing
    - Pacer pads
    - Consider pacing PAC in high risk patients

#### MANAGEMENT OF ANESTHESIA

- **Induction**
  - Ensure patient has deep plane of anesthesia prior to airway manipulation
- **Maintenance**
  - Volatiles well tolerated due to myocardial depressant properties although be wary of arrhythmogenic potential
- **Emergence**
  - Avoid sympathetic activation

#### DISPOSITION & MONITORING

- Good pain control with PCA or epidural (watch for hypotension) to avoid SNS activation and tachycardia
- Major surgery with potential for pain, fluid shifts should be admitted to a monitored High dependency unit
- Intermediate and minor procedures may be discharged to the ward or home


#### COMPLICATIONS

- Acute LVOT obstruction / SAM
  - Always consider LVOT obstruction as primary cause of hypotension
  - Should be treated with aggressive volume, vasopressors (e.g. phenylephrine) and beta-blocker (esmolol) or CCB (verapamil)
  - Temporary dual chamber pacing (can decrease LVOT obstruction by 50%, but no improvement in functional capacity)
- Ischemia
  - Once again, ensure that hemodynamic goals are optimized
  - Patients likely require increased SVR to perfuse hypertrophic myocardium
  - Important to treat precipitating factors quickly as this can lead to arrhythmias or worsening LVOT obstruction
- Arrhythmia
  - Poorly tolerated
  - Treat immediately with volume (often due to hypovolemia) and cardioversion

#### PATHOPHYSIOLOGY

- HOCM (a.k.a. IHSS) is an autosomal dominant genetic disorder of cardiac sarcomeres of which a subset of patients (~25%) have a dynamic obstruction to left ventricular outflow
- Many patients may have minor or no symptoms (many individuals diagnosed during family screening)
- Variability in age of onset
  - Severity and progression of symptoms varies markedly with genetic abnormality
- Resting pressure gradient between LV outflow tract and aorta present in only ~25% of patients whereas other patients only have a gradient with exertion
- No predictable correlation between the degree of obstruction and symptoms:
  - Some patients with severe LVOT obstruction remain asymptomatic
  - Sudden death or cardiac arrest may be the initial presentation in some patients
- **LVOT Obstruction**
  - Dyspnea on exertion (90%)
  - Pre-syncope or syncope
  - Postural light-headedness
- **Hypertrophy**
  - Chest pain (25-30%)
    - Majority have normal angiogram
    - Commonly precipitated or worsened by heavy meals
  - Diastolic dysfunction
- **Arrhythmias**
  - Supraventricular Arrhythmias (A-fib, A-flutter)
    - Common (up to 25%)
    - May be associated with increased mortality
    - May be poorly tolerated d/t presence of physiologic changes:

- Diastolic dysfunction
    - Increased HR
  - Can proceed to ventricular arrhythmias
- **Ventricular Arrhythmias**
  - Ventricular premature beats
    - Common in patients with HOCM
    - No evidence that frequent VPB are at increased risk for sustained ventricular arrhythmias
  - Non-sustained VT
    - 15-25% of patients
    - Increased risk for sudden cardiac death (8.6% per year vs. 1% per year)
- **Sudden Cardiac Death**
  - Risk factors
    - Syncope and / or family history of sudden cardiac death
    - LV wall thickness > 30 mm
    - Non-sustained ventricular tachycardia
    - Abnormal blood pressure response with exercise
  - AICD
    - Secondary prevention in survivors of cardiac arrest or sustained VT
    - Primary prevention in high risk patients
- **Management of HOCM**
  - LVOT obstruction
    - Pharmacotherapy
      - Beta-blockers
      - Calcium channel blockers
      - Disopyramide
        - antiarrhythmic with negative inotropic properties
    - Surgical Therapy
      - LV myectomy +/- MVR
      - Septal ablation with EtOH
  - Hypertrophy
    - Diuretics in patients with diastolic dysfunction
  - Arrhythmias
    - Amiodarone
    - Anticoagulants
    - Pacemaker
    - AICD



**Ethanol ablation in HCM** Representation of ethanol ablation via a septal coronary artery in hypertrophic cardiomyopathy (HCM). A section of hypertrophied left ventricle is shown, while the inset demonstrates a balloon occluding a septal coronary artery and ethanol-induced infarction. (Reproduced with permission from: Braunwald, E. Hypertrophic cardiomyopathy--the benefits of a multidisciplinary approach. N Engl J Med 2002; 347:1306. Copyright © 2002 Massachusetts Medical Society.)

#### REFERENCES

- Uptodate
- Roizen, Essence of Anesthesia